Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

New data fuel hopes for broad use of Novartis psoriasis drug

Novartis is increasingly confident about the potential of its new injectable drug Cosentyx, as fresh clinical data confirms its long-term benefits in treating psoriatic arthritis. Cosentyx was approved by the U.S. Food and Drug Administration in January for treating the painful skin condition plaque psoriasis, but the company also has high hopes for the product […]

Read More »

Study: Middle Age Memory Failures Can Predict Alzheimer’s 18 Years Before Diagnosis

Results from an extensive new study suggest that early symptoms of Alzheimer’s disease appear up to 18 years before the disease is officially diagnosed. Researchers publishing in the journal Neurology gave 2,125 people, average age 73, a test of memory and thinking skills every three years for 18 years. All of the participants were either […]

Read More »

Study: Middle Age Memory Failures Can Predict Alzheimer’s 18 Years Before Diagnosis

Results from an extensive new study suggest that early symptoms of Alzheimer’s disease appear up to 18 years before the disease is officially diagnosed. Researchers publishing in the journal Neurology gave 2,125 people, average age 73, a test of memory and thinking skills every three years for 18 years. All of the participants were either […]

Read More »

Mom’s diabetes control in pregnancy may affect kids’ brains

For pregnant women with type 1 diabetes, good control of blood sugar might make a difference in how well their child does in school years later, according to new research from Denmark. Overall, children born to mothers with type 1 diabetes achieved similar grades in primary school when compared to other children, the study found, […]

Read More »

Older stroke patients may not get needed anti-clotting drugs

Following a first stroke, older, poorer and less educated patients may have lower odds of getting clot-busting drugs to help prevent another blockage of blood to the brain, a Swedish study suggests “Our findings confirm socioeconomic inequalities in prescription of anticoagulants,” lead study author Maria Sjolander, a researcher in statistics and pharmacology at Umea University, […]

Read More »

The Medicines Company May Sell European Business As Management Focuses Inward

Parsippany, N.J.-based The Medicines Company (MDCO) is considering selling its European business, Bloomberg News reported this week, and is working with consulting bank Rothschild to evaluate options. The Medicines Company’s lead product is Angiomax, an anticoagulant that brought in $636 million last year, primarily in the U.S. It is marketed in Europe as Angiox. Earlier […]

Read More »

Europe gives green light to new Novartis, Alexion drugs

New drugs from Novartis and Alexion won a green light from European regulators on Friday, delivering a boost to both drugmakers and offering new treatment options for cancer and rare diseases. Experts from the European Medicines Agency (EMA) said they had recommended approval of Novartis’s Farydak for multiple myeloma, an aggressive blood cancer, and Odomzo […]

Read More »

New Sanofi CEO to unveil five-year plan in November

Sanofi Chief Executive Olivier Brandicourt has told unions he will present a five-year strategic plan in November after the French company’s third-quarter results, labour representatives said. Brandicourt said shortly after taking the helm of the drugs company in April that he was launching a strategic review to be completed in the fourth quarter. His plan […]

Read More »

External Innovation: Force Multiplier For R&D

External models of R&D innovation are the rage in Pharma today, as they should be – the future of our industry depends on a great deal more rather than less collaboration. In a very healthy way, lots of experiments are being done across the ecosystem and the final scorecard for what worked and what didn’t […]

Read More »

Sanguine Corp. Inc. Announces Name Change to New Alliance BioSciences

Reflecting Their Broader Scope of Research and Development, Sanguine Corp. Inc. Obtains Shareholder Approval to Change Name to New Alliance BioSciences ATLANTA, GA–(Marketwired – June 26, 2015) – Sanguine Corp., Inc. (OTC PINK: SGUI) announced today that it has obtained shareholder approval to change the name of the Company to New Alliance BioSciences. Frank Marra, […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom